Drug intelligence / Profile preview

netarsudil + latanoprost

Development stage
Approved
Lead developer
Alcon
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Ophthalmic
01

Overview

Netarsudil + latanoprost is a fixed-dose combination ophthalmic solution used to reduce elevated intraocular pressure in adults with primary open-angle glaucoma or ocular hypertension. The drug combines two active ingredients: netarsudil, a Rho kinase inhibitor that increases trabecular outflow by reducing cell contraction and stiffness in the trabecular meshwork, and latanoprost, a prostaglandin F2α analogue that increases uveoscleral outflow of aqueous humor. This dual mechanism provides additive effects for lowering intraocular pressure. The combination is administered as eye drops once daily[1][2][3][5][8].

Brand names
RocklatanRoclanda
Other names
netarsudil/latanoprostlatanoprost and netarsudil ophthalmic
02

Targets

PTGFR (Prostaglandin F2 alpha receptor)NET (Norepinephrine Transporter)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on netarsudil + latanoprost.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on netarsudil + latanoprost.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call